Versant Ventures is a leading healthcare and biotechnology venture capital firm founded in 1999 and headquartered in San Francisco. The firm invests in game-changing biopharmaceuticals, medical devices, and other life sciences companies, leveraging in-house Discovery Engines to launch novel biotech companies with academic founders.
39% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $52.6M (across 192 rounds with reported amounts).
Portfolio
136
Fund Size
—
Top Stage
Series A
Last 12 Mo
6
Team
Andrew Jefferson
Operating Partner
Nikita Sharma
Principal
Lara Hoth
VP, Management Company Finance and Accounting
Steve Edelson
VP, IR & Communications
Cathy Dring
Legal Counsel
Kim Macniak
Controller
Max Eisenberg
Chief Operating Officer and General Counsel
Rich Van Doren
Chief Financial Officer
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
| DDayra Therapeutics | Unknown | $70M | Nov 2025 |
 Gate Bioscience | Series B | $65M | Nov 2025 |
| DDualitas | Series A | $65M | Sep 2025 |
 Dualitas Therapeutics | Series A | $65M | Sep 2025 |
| AAllrock Bio | Series A | $50M | Sep 2025 |
 AllRock | Series A | $50M | Sep 2025 |
 Granite Bio | Series A | $30M | Apr 2025 |
| Granite Bio | Series B | $70M | Apr 2025 |
 Helicore Biopharma | Series A | $65M | Jan 2025 |
 Contineum Therapeutics | Series B | $30M | Jan 2025 |
 Insulet | Unknown | $50M | Jan 2025 |
| Helicore Biopharma | Series A | $65M | Jan 2025 |
| AAllrock Bio | Series A | $50M | Jan 2025 |
| Dualitas Therapeutics | Series A | $65M | Jan 2025 |
| AllRock | Series A | $50M | Jan 2025 |
 Antag Therapeutics | Series A | — | Dec 2024 |
 Fable Therapeutics | Seed | $53.5M | Oct 2024 |
| Fable Therapeutics | Series A | $53.5M | Oct 2024 |
| BBright Peak Therapeutics | Series C | $90M | Jun 2024 |
 Firefly Bio | Unknown | $94M | Feb 2024 |
 Enterprise Therapeutics | Series B | $26M | Jan 2024 |
| Firefly Bio | Series A | $94M | Jan 2024 |
| SSixpeaks Bio | Series A | $30M | Jan 2024 |
| BBright Peak Therapeutics | Series C | $90M | Jan 2024 |
 Gritstone Oncology | Series B | $92.7M | Jan 2024 |
Top Co-Investors
Last updated: 7 October 2026